Can-Fite BioPharma Ltd.

CANFSEC EDGAR

Pharmaceutical Preparations(L3)CIK: 1536196

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenues	$810.0K	—	$763.0K	$2.0M	$3.8M
Research and Development Expense	$7.8M	$9.8M	$12.0M	$11.0M	$6.1M
Selling, General and Administrative Expense	—	—	$317.0K	—	—
Operating Expenses	$10.9M	—	—	—	—
Operating Income (Loss)	-$10.1M	-$12.8M	-$14.1M	-$12.0M	-$5.4M
Nonoperating Income (Expense)	-$77.0K	$227.0K	-$304.0K	-$618.0K	-$1.2M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$10.2M	-$12.6M	-$14.4M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$10.0M	$9.3M	$20.3M	$9.5M	$8.2M
Assets, Current	$9.9M	$9.2M	$20.1M	$9.4M	$7.1M
Cash and Cash Equivalents, at Carrying Value	$4.3M	$3.0M	$4.4M	$8.3M	$3.5M
Accounts Receivable, after Allowance for Credit Loss	$0.00	—	—	—	—
Liabilities, Current	$2.0M	$2.5M	$2.7M	$1.3M	$3.3M
Stockholders' Equity Attributable to Parent	$14.4M	$6.1M	$2.4M	$3.0M	$3.0M
Common Stock, Shares, Outstanding	$1.4B	$815.7M	$815.7M	$463.8M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$10.8M	-$9.9M	-$12.1M	-$11.1M	-$4.2M
Net Cash Provided by (Used in) Investing Activities	$9.5M	-$14.5M	-$26.0K	-$3.0K	-$33.0K
Net Cash Provided by (Used in) Financing Activities	$9.1M	$20.5M	$17.7M	$10.2M	$4.4M
Payments to Acquire Property, Plant, and Equipment	$9.0K	$11.0K	$26.0K	$3.0K	$33.0K
Payments of Dividends	—	$2.6M	$715.0K	$715.0K	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)